The kinase inhibitor O 6-cyclohexylmethylguanine ( NU 2058 ) potentiates the cytotoxicity of cisplatin by mechanisms that are independent of its effect upon CDK 2

O-Cyclohexylmethylguanine (NU2058) was developed as an inhibitor of CDK2 and was previously shown to potentiate cisplatin cytotoxicity in vitro. The aim of this study was to investigate the mechanism of cisplatin potentiation by NU2058. SQ20b, head and neck cancer cells were treated for 2 h with NU2058 (100 mM) and then for a further 2 h with cisplatin and NU2058. NU2058 increased cisplatin cytotoxicity, by clonogenic assay, with a dose modification factor (DMF) of 3.1. NU2058 increased total intracellular platinum levels 1.5-fold, and platinum–DNA adduct levels twofold. Furthermore, the cisplatin–DNA adducts formed were more toxic in the presence of NU2058. To investigate whether the effects of NU2058 on cisplatin adduct levels and toxicity were dependent on CDK2 activity, additional CDK2 inhibitors were tested. NU6230 (CDK2 IC50 18 mM) was equipotent to NU2058 (CDK2 IC50 17 mM) as a CDK2 inhibitor in cell-free and cell-based assays, yet did not potentiate cisplatin cytotoxicity. Furthermore, NU6102 was >1000-fold more potent than NU2058 as a CDK2 inhibitor (CDK2 IC50 5 nM) yet was no more active than NU2058 in potentiating cisplatin. NU2058 also potentiated melphalan (DMF 2.3), and monohydroxymelphalan (1.7), but not temozolomide or ionising radiation. Whilst NU2058 increased melphalan cytotoxicity, it did not increase melphalan–DNA adduct formation. These studies demonstrate that NU2058 alters the transport of cisplatin, causing more Pt–DNA adducts, as well as sensitizing cells to cisplatinand melphalan-induced DNA damage. However, the effects of NU2058 are independent of CDK2 inhibition. 2009 Elsevier Inc. All rights reserved.

[1]  M. Dolan,et al.  Molecular mechanisms of resistance and toxicity associated with platinating agents. , 2007, Cancer treatment reviews.

[2]  Thomas S. Lin,et al.  Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. , 2007, Blood.

[3]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[4]  G. Shapiro,et al.  Cyclin-dependent kinase pathways as targets for cancer treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Tilby,et al.  Specific adducts recognised by a monoclonal antibody against cisplatin-modified DNA. , 2005, Biochemical pharmacology.

[6]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[7]  Dong Wang,et al.  Cellular processing of platinum anticancer drugs , 2005, Nature Reviews Drug Discovery.

[8]  N. Curtin,et al.  Effect of Cell Cycle Inhibition on Cisplatin-Induced Cytotoxicity , 2005, Journal of Pharmacology and Experimental Therapeutics.

[9]  K. Gould,et al.  p53 Elevation in Relation to Levels and Cytotoxicity of Mono- and Bifunctional Melphalan-DNA Adducts , 2004, Molecular Pharmacology.

[10]  G. Samimi,et al.  The role of copper transporters in the development of resistance to Pt drugs. , 2004, Journal of inorganic biochemistry.

[11]  Dong Wang,et al.  Cisplatin-induced Post-translational Modification of Histones H3 and H4* , 2004, Journal of Biological Chemistry.

[12]  T. Boulikas,et al.  Cisplatin and platinum drugs at the molecular level. (Review). , 2003, Oncology reports.

[13]  Z. Siddik,et al.  Cisplatin: mode of cytotoxic action and molecular basis of resistance , 2003, Oncogene.

[14]  E. Zuhowski,et al.  Enhancement of platinum-induced cytotoxicity by O6-benzylguanine. , 2003, Molecular cancer therapeutics.

[15]  Jane A. Endicott,et al.  Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor , 2002, Nature Structural Biology.

[16]  L. Einhorn.  Curing metastatic testicular cancer , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[17]  A H Calvert,et al.  Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. , 2000, Journal of medicinal chemistry.

[18]  B. Rollins,et al.  Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  S. Kaufmann,et al.  Antineoplastic Agents: the Importance of Sequence of Administration' , 2022 .

[20]  Sibylle Mittnacht,et al.  Differential Phosphorylation of the Retinoblastoma Protein by G1/S Cyclin-dependent Kinases* , 1997, The Journal of Biological Chemistry.

[21]  M. Grever,et al.  Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  S. Aebi,et al.  The role of DNA mismatch repair in platinum drug resistance. , 1996, Cancer research.

[23]  M. Tilby,et al.  Immunological detection of DNA damage caused by melphalan using monoclonal antibodies. , 1987, Cancer research.

[24]  D. Lydall,et al.  Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. , 1986, Cancer research.

[25]  P. Lohman,et al.  Detection and quantification of adducts formed upon interaction of diamminedichloroplatinum (II) with DNA, by anion-exchange chromatography after enzymatic degradation. , 1982, Nucleic acids research.

[26]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[27]  S. Howell,et al.  Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. , 2005, Critical reviews in oncology/hematology.

[28]  M. Tilby,et al.  Application of a sensitive immunoassay to the study of DNA adducts formed in peripheral blood mononuclear cells of patients undergoing high-dose melphalan therapy. , 1993, European journal of cancer.

[29]  F. Friedlos,et al.  Quantitative estimation of cisplatin-induced DNA interstrand cross-links and their repair in mammalian cells: relationship to toxicity. , 1987, Pharmacology & therapeutics.